In conclusion, this study demonstrated that chronic administration of eritoran significantly attenuated liver inflammation and fibrosis in the FFD- and CCl4-indued liver fibrosis models by suppressing the MyD88–NF-κB pathway in the liver, HSCs and KCs. The gene discussed is MYD88; the disease is Hepatic fibrosis.